BD Oncomark CD79b/Anti-Lambda/ CD19

Transcription

1 BD Oncomark CD79b/Anti-Lambda/ CD19 4/ IVD Catalog No BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company BD Becton, Dickinson and Company BD Biosciences 2350 Qume Drive San Jose, CA USA Benex Limited Pottery Road, Dun Laoghaire, Co. Dublin, Ireland Tel Fax BD Biosciences European Customer Support Tel Fax Becton Dickinson Pty Ltd, 4 Research Park Drive, Macquarie University Research Park, North Ryde NSW 2113, Australia Becton Dickinson Limited, 8 Pacific Rise, Mt. Wellington, Auckland, New Zealand bdbiosciences.com ClinicalApplications@bd.com 1. INTENDED USE BD Oncomark CD79b FITC/Anti- Lambda PE/CD19 PerCP-Cy 5.5 * is intended for in vitro flow cytometric immunophenotyping of hematologic disorders. 1,2 2. COMPOSITION CD79b, clone SN8 (3A2-2E7-1F5), is generated from the fusion of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with an antigen prepared from the membrane of B-prolymphocytic leukemia (B-PLL) cells. 3 Anti-Lambda, clone , is derived from the hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from BALB C/J mice immunized with human IgA 1 -λ myeloma protein. CD19, clone SJ25C1, 4 is derived from the hybridization of mouse Sp2/0 cells with spleen cells from BALB/c mice immunized with NALM1 + NALM16 cells. CD79b and CD19 are each composed of mouse IgG 1 heavy chains and kappa light chains. Anti-Lambda is composed of mouse IgG 1 heavy chains and lambda light chains. * Cy is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for in vitro diagnostics. It is not licensed for any other use. If you require any additional license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded. 1

2 This reagent is supplied as a combination of CD79b FITC, Anti-Lambda PE, and CD19 PerCP-Cy5.5 in 1 ml of phosphate-buffered saline (PBS) containing bovine serum albumin (BSA) and 0.1% sodium azide. Antibody purity is as follows. FITC, PE, PerCP-Cy5.5: 20% free fluorophore at bottling, as measured by size-exclusion chromatography (SEC) 3. STORAGE AND HANDLING The antibody reagent is stable until the expiration date shown on the label when stored at 2 C 8 C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry. Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration. 4. REAGENTS OR MATERIALS REQUIRED BUT NOT PROVIDED Falcon disposable 12 x 75-mm polystyrene test tubes or equivalent Micropipettor with tips Vortex mixer BD FACS lysing solution (10X) (Catalog No ). For dilution instructions and warnings, refer to the instructions for use (IFU). Centrifuge BD CellWASH (Catalog No ) or a wash buffer of PBS with 0.1% sodium azide BD CellFIX (Catalog No ) or 1% paraformaldehyde solution in PBS with 0.1% sodium azide. Store at 2 C 8 C in amber glass for up to 1 week. Properly equipped cytometer. Flow cytometers must have laser excitation set at 488 nm and must be equipped to detect light scatter and the appropriate fluorescence, and have the appropriate analysis software installed for data acquisition and analysis. Refer to your instrument user s guide for instructions. 5. SPECIMEN(S) BD Oncomark CD79b FITC/ Anti-Lambda PE/CD19 PerCP-Cy5.5 can be used for immunophenotyping by flow cytometry with peripheral blood and bone marrow aspirates collected in BD Vacutainer EDTA tubes. Each type of specimen can have different storage conditions and limitations that should be considered prior to collection and analysis. 1,2 WARNING All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection 5,6 and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves. Falcon is a registered trademark of Corning Incorporated. 2

3 6. PROCEDURE Viability of samples should be assessed and a cutoff value established. A cutoff value of at least 80% viable cells has been suggested. 1 To avoid serum interference when using these reagents, it is necessary to pre-wash the sample using at least 25 volumes excess 1X PBS with 0.1% sodium azide (48 ml of 1X PBS with sodium azide per 2 ml of whole blood to be washed). Mix well. Pellet cells by centrifugation and resuspend in 1X PBS with 0.1% sodium azide to the original volume. 1. Add 20 µl of BD Oncomark CD79b/ Anti-Lambda/CD19 reagent to 100 µl of whole blood or prefiltered bone marrow in a 12 x 75-mm tube. 2. Vortex gently and incubate for minutes in the dark at room temperature (20 C 25 C). 3. Add 2 ml of 1X BD FACS lysing solution. 4. Vortex gently and incubate for 10 minutes in the dark at room temperature. 5. Centrifuge at 300g for 5 minutes. Remove the supernatant. 6. Add 2 3 ml of BD CellWASH solution (or wash buffer) and centrifuge at 200g for 5 minutes. Remove the supernatant. 7. Add 0.5 ml of BD CellFIX solution (or 1% paraformaldehyde solution) and mix thoroughly. Store at 2 C 8 C until analyzed. Stained samples should be analyzed within 24 hours of staining. Flow Cytometric Analysis 1. Set up the instrument as recommended by the manufacturer. Run a control sample daily from a normal adult subject or a commercially available whole blood control to optimize instrument settings and as a quality control check of the system. 2. Vortex the cells thoroughly at low speed to reduce aggregation before running them on the flow cytometer. 3. Run the sample on the flow cytometer. Verify that all populations are on scale. Optimize the instrument settings, if needed. 4. Acquire and analyze list-mode data using appropriate software. 5. On the appropriate plots, use the required combination of gates, regions or quadrants to isolate the population of interest (Figure 1). Figure 1 Dot plots displaying region R1 and quadrants 3

4 6. Determine antigen expression based on the sample negative population. 7. PERFORMANCE CHARACTERISTICS Specificity CD79b, clone SN8, reacts with the CD79b protein and the epitope lies on the extra domain of the peptide. 7 CD79b is helpful in delineating signal transduction pathway activated via antibody receptors during different stages of B-cell differentiation. 8 Anti-Lambda is specific for lambda light chains of human immunoglobulins. 9 CD19 (SJ25C1) recognizes a 90-kilodalton (kda) antigen that is present on human B lymphocytes. 4,10 Antigen Distribution The CD79b antigen is expressed on surface Ig (sig) positive lymphocytes and B-cell lines. It can also be found in the cytoplasm of sig-negative cells, including most terminal deoxynucleotidyltransferase (TdT) positive early pre-b and all cytoplasmic µ-positive pre-b cell lines. 7 The vast majority of chronic lymphocytic leukemia cells are CD79b-negative while cells from other B-cell disorders usually express high levels of the CD79b antigen. 11 Immunoglobulins bearing lambda light chains are present on approximately 40% of normal B lymphocytes and on Igλ + neoplastic cells In serum, Anti-Lambda reacts with immunoglobulins bearing lambda light chains as well as free lambda light chains. The CD19 antigen is present on approximately 7% 23% of human peripheral blood lymphocytes 19 and on splenocytes. 20 The CD19 antigen is present on human B lymphocytes at most stages of maturation. 4,21 CD19 does not react with resting or activated T lymphocytes, granulocytes, or monocytes. 4,21 8. LIMITATIONS Use of therapeutic monoclonal antibodies in patient treatment can interfere with recognition of target antigens by this reagent. This should be considered when analyzing samples from patients treated in this fashion. BD Biosciences has not characterized the effect of the presence of therapeutic antibodies on the performance of this reagent. Use of this reagent combination for diagnostic evaluation of hematologic disorders should be performed in the context of a thorough immunophenotypic analysis including other relevant markers. Procedures using the BD Oncomark reagents must adhere to the instructions for use for the specific instrument, software, and quality control procedures used by your laboratory. Reagent performance data was collected typically with EDTA-treated specimens. Reagent performance can be affected by the use of other anticoagulants. Samples with large numbers of nonviable cells can give erroneous results due to selective loss of populations and to increased nonspecific binding of antibodies to nonviable cells. 4

5 WARRANTY Unless otherwise indicated in any applicable BD general conditions of sale for non-us customers, the following warranty applies to the purchase of these products. THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT. TROUBLESHOOTING Problem Possible Cause Solution Poor resolution between debris and lymphocytes Staining dim or fading Cell interaction with other cells and platelets Rough handling during cell preparation Inappropriate instrument settings Cell concentration too high at staining step Insufficient reagent Cells not analyzed within 24 hours of staining Few or no cells Cell concentration too low Cytometer malfunctioning Prepare and stain another sample. Check cell viability; centrifuge cells at lower speed. Follow proper instrument setup procedures; optimize instrument settings as required. Check and adjust cell concentration or sample volume; stain with fresh sample. Repeat staining with increased amount of antibody. Repeat staining with fresh sample; analyze promptly. Resuspend fresh sample at a higher concentration; repeat staining and analysis. Troubleshoot instrument. REFERENCES 1. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10: Stelzer GT, Marti G, Hurley A, McCoy P Jr, Lovett EJ, Schwartz A. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30: Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood. 1993;81: Nadler LM. B Cell/Leukemia Panel Workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. New York, NY: Springer-Verlag; 1986;2: Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute; CLSI document M29-A3. 6. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37: Engel P, Wagner N, Tedder TF. CD79 Workshop report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995: Sanchez M, Misulovin Z, Burkhardt AL, et al. Signal transduction by immunoglobulin is mediated through Ig alpha and Ig beta. J Exp Med. 1993;178: Kubagawa H, Gaithings WE, Levitt D, Kearney JF, Cooper MD. Immunoglobulin isotype expression of normal pre-b cells as determined by immunofluorescence. J Clin Immunol. 1982;2: Moldenhauer G, Dörken B, Schwartz R, Pezzutto A, Knops J, Hammerling GJ. Analysis of ten B lymphocyte-specific workshop monoclonal antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. New York, NY: Springer-Verlag; 1986;2:

6 11. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia. 1996;10: Chung J, Gong G, Huh J, Khang SK, Ro JY. Flow cytometric immunophenotyping in fine-needle aspiration of lymph nodes. J Korean Med Sci. 1999;14: Zardawi IM, Jain S, Bennett G. Flow-cytometric algorithm on fine-needle aspirates for the clinical workup of patients with lymphadenopathy. Diagn Cytopathol. 1998;19: Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E. Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction. Diagn Mol Pathol. 1999;8: Braylan RC, Benson NA, Iturraspe J. Analysis of lymphomas by flow cytometry: current and emerging strategies. Ann NY Acad Sci. 1993;677: Johnson A, Cavallin-Stahl E, Akerman M. Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-hodgkin's lymphoma. Br J Cancer. 1985;52: Letwin BW, Wallace PK, Muirhead KA, Hensler GL, Kashatus WH, Horan PK. An improved clonal excess assay using flow cytometry and B-cell gating. Blood. 1990;75: Geary WA, Frierson HF, Innes DJ, Normansell DE. Quantitative criteria for clonality in the diagnosis of B-cell non- Hodgkin's lymphoma by flow cytometry. Mod Pathol. 1993;6: Reichert T, DeBruyère M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopath. 1991;60: Tedder T, Zhou L-J, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994;15: Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B-lymphocyte development. Blood. 1987;70: